High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody

American Journal of Obstetrics and Gynecology

Volumn 203, Issue 6, 2010, Pages 582.e1-582.e7

  Richter, Christine E ^a   Cocco, Emiliano ^a   Bellone, Stefania ^a   Silasi, Dan Arin ^a   Rüttinger, Dominik ^b   Azodi, Masoud ^a   Schwartz, Peter E ^a   Rutherford, Thomas J ^a   Pecorelli, Sergio ^c   Santin, Alessandro D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MICROMET AG   (Germany)

^c UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Adecatumumab; Chemotherapy; Cytotoxicity; EpCAM; Monoclonal antibody; MT201; Natural killer cell; Ovarian cancer

Indexed keywords

ADECATUMUMAB; EPITHELIAL CELL ADHESION MOLECULE; INTERLEUKIN 2; MESSENGER RNA; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; MONOCLONAL ANTIBODY; MT201 ANTIBODY, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RESISTANCE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; NATURAL KILLER CELL; OVARY CARCINOMA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; CANCER STAGING; DRUG EFFECT; DRUG RESISTANCE; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; OVARY TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 79952116596     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2010.07.041     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Cho KR, Shih I-M. Ovarian cancer. Annu Rev Pathol 2009;4:287-313.
3. Martin LP, Schilder RJ. Management of recurrent ovarian carcinoma: current status and future directions. Semin Oncol 2009;36:112-25.
4. Kim J-H, Herlyn D, Wong K-K, et al. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 2003;9:4782-91. (Pubitemid 37323281)
5. Armstrong A, Eck SL. EpCAM: a new therapeutic target for an old cancer antigen. Cancer Biol Ther 2003;2:320-5.
6. Muenz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009;69:5627-9.
7. Muenz M, Fellinger K, Hofmann T, Schmitt B, Gires O. Glycosylation is crucial for stability of tumor and cancer stem cell antigen EpCAM. Front Biosci 2008;13:5195-201. (Pubitemid 351599669)
8. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer 2007;96: 417-23. (Pubitemid 46215211)
9. Trzpis M, McLaughlin PMJ, de Leij LMHF, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 2007;171:386-95. (Pubitemid 47344671)
10. Litvinov SV, Balzar M, Winter MJ, et al. Epithelial cell adhesion molecule (EpCAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997;139:1337-48. (Pubitemid 27523219)
11. Osta WA, Chen Y, Mikhitarian K, et al. Ep-CAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818-24. (Pubitemid 39095582)
12. Riethmueller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Duke's C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-94.
13. Naundorf S, Preithner S, Mayer P, et al. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. In J Cancer 2002;100:101-10. (Pubitemid 34602073)
14. Schmidt M, Scheulen ME, Dittrich C, et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol 2010;21: 875-82.
15. Marschner N, Rüttinger D, Zugmaier G, et al. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate specific antigen after radical prostatectomy. Urol Int 2010, July 2 [Epub ahead of print].
16. Sebastian M, Hanusch C, Schmidt, et al. Safety and antitumor activity of 3 weekly anti-EpCAM antibody adecatumumab in combination with docetaxel for patients with metastatic breast cancer: results of a multicenter phase Ib trial. J Clin Oncol 2009;27(suppl):15s.
17. Bellone S, Siegel ER, Cocco E, et al. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/ chemotherapy-resistant epithelial ovarian cancer. Int J Gynecol Cancer 2009;19:860-6.
18. Spizzo G, Went P, Dirnhofer S, et al. Overexpression of epithelial cell adhesion molecule (EpCAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 2006;103: 483-8. (Pubitemid 44602156)
19. Maetzel D, Denzel S, Mack B, et al. Nuclear signaling by tumour-associated antigen Ep-CAM. Nat Cell Biol 2009;11:162-71.
20. Piyathilake CJ, Frost AR, Weiss H, Manne U, Heimburger DC, Grizzle WE. The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung. Hum Pathol 2000;31:482-7. (Pubitemid 30262871)
21. Xiang W, Wimberger P, Dreier T, et al. Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells. J Cancer Res Clin Oncol 2003;129:341-8. (Pubitemid 36963196)
22. Preithner S, Elm S, Lippold S, et al. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol 2006;43:1183-93. (Pubitemid 43063171)
23. Caligiuri MA, Murray C, Robertson MJ, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993; 91:123-32. (Pubitemid 23037263)
24. Boyman O, Surh CD, Sprent J. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther 2006; 6:1323-31. (Pubitemid 44875686)
25. Hoojberg E, Sein JJ, van den Berk PCM, et al. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. Cancer Res 1995;55:2627-34.
26. Choe B, Frost P, Morrison N, Rose N. Natural killer cell activity of prostatic cancer patients. Cancer Invest 1987;5:285-8.
27. Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA 1986;83:7893-7. (Pubitemid 17183949)
28. Burges A, Wimberger P, Kuemper C, et al. Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res 2007;13:3899-905. (Pubitemid 47037597)